Butyrate supplementation reshapes systemic metabolism and attenuates cardiac aging

Butyrate supplementation starting at 18 months extends survival and improves systemic metabolism and cardiac aging phenotypes in male and female mice, including reduced hypertrophy and dysfunction.

• Why it matters: Interventions that extend healthspan and preserve cardiac function during aging are needed, but the mechanisms linking late-life metabolic changes to cardiac remodeling remain unclear.
• What they did: Late-life mice received butyrate supplementation beginning at 18 months; outcomes included survival, metabolic and performance measures, plus plasma/myocardial metabolomics and lipidomics, cardiac proteomics, and full-length RNA sequencing.
• The result: Butyrate reduced adiposity and fasting glucose and attenuated age-associated cardiac hypertrophy, fibrosis, and systolic/diastolic dysfunction, with improved mitochondrial structure and respiration; benefits on LV hypertrophy and diastolic indices required ATG7.

AI summary of the abstract · may contain errors · not medical advice · read the paper.